Kishor Bhatia
Fortuna: - $ al 31/10/2026
Fortuna: - $ al 31/10/2026
Kishor G.
Bhatia is Chief Scientific Officer at Lantern Pharma, Inc. since 2019.
Formerly, Dr. Bhatia was Director of the AIDS Malignancy Program at the National Cancer Institute from 2007 to 2016.
Prior to that, Dr. Bhatia was Research Assistant Professor at Georgetown University from 1985 to 1989.
Education includes a doctorate from the University of Mumbai and an undergraduate degree from the University of Pune.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LANTERN PHARMA, INC. -.--% | 05/10/2026 | 0 ( -.--% ) | - $ | 31/10/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LANTERN PHARMA INC. | Director Técnico/Científico/I+D | 01/12/2019 |
| Empresas | Cargo | Fin |
|---|---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Corporate Officer/Principal | 01/07/2016 |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1989 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
University of Mumbai
University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
University of Pune
University of Pune Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lantern Pharma, Inc.
Lantern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drug from advanced genomics and artificial intelligence | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.